Ratings Surperformance

Trader
Investor
-
Global
-
Quality
ESG MSCI
BB

Ratings ESG MSCI

Ratings Legend Biotech Corporation: Strengths and Weaknesses

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company's MSCI ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Highlights: Legend Biotech Corporation
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses: Legend Biotech Corporation
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company appears highly valued given the size of its balance sheet.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Rating Financials

Legend Biotech Corporation SectorUnited States
Fundamentals -
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE-
ROE
Financial Health-
Gearing
Leverage-
Capital Intensity-
Balance sheet growth
Long Term balance sheet growth-
Long term revenue growth-
Long term EPS growth-
More ratings

Rating Valuation

Legend Biotech Corporation SectorUnited States
Global Valuation -
Enterprise value-
EV/Revenue
EV/EBITDA-
EV/FCF-
Equity Valuation-
P/E-
PBR
Dividend Yield-
EV/EBIT-
CAPEX/Revenue
More ratings

Rating Consensus

Legend Biotech Corporation SectorUnited States
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Legend Biotech Corporation SectorUnited States
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Legend Biotech Corporation SectorUnited States
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
5.2B -
BB
- -
54.89B
AA
43.51B -
BBB
- -
38.12B
AAA
23.14B - - - -
19.5B
AA
17.25B
AAA
14.68B
B
-
14.12B - - - -
13.78B -
A
- -
Average 24.42B
A
Weighted average by Cap.
A
See all sector ratings
  1. Stock Market
  2. Equities
  3. LEGN Stock
  4. Ratings Legend Biotech Corporation